Johnson & Johnson (JNJ) said that Health Canada has issued a Notice of Compliance for CARVYKTI (ciltacabtagene autoleucel) for the ...

In this newly created role, Mr. Bash will be responsible for managing the continued growth of CARVYKTI ®, overseeing Legend Biotech’s commercial, technical operations, and quality functions of ...

Turning to our highlights. In the third quarter, we are pleased that CARVYKTI cells continued their strong momentum, delivering quarter-over-quarter growth of 53% and year-over-year growth of 87%.

Net Trade Sales of CARVYKTI: Approximately $286 million, an 87.6% increase year-over-year and a 53.2% increase quarter-over-quarter. Total Revenues: $160 million, consisting of $143 million in ...

In a recent earnings call, Legend Biotech (NASDAQ: LEGN) reported a significant increase in net sales for its CARVYKTI treatment, with a notable 87.6% year-over-year growth, reaching approximately ...

In a recent earnings call, Legend Biotech (NASDAQ: LEGN) reported a significant increase in net sales for its CARVYKTI treatment, with a notable 87.6% year-over-year growth, reaching approximately ...

Truist Securities analyst Asthika Goonewardene in an investor note said data for anito-cel—particularly its safety profile—will help differentiate the CAR T therapy from Legend Biotech and J&J’s ...

After seeing the data, analysts underscored the therapy’s best-in-class potential compared to Johnson & Johnson and Legend Biotech's FDA-approved treatment Carvykti. Abstract data from early and ...

Their CARVYKTI therapy, which targets BCMA, has been approved by both the FDA and European Commission, and is expanding its reach globally. This development highlights potential growth ...

New data will showcase significantly increased and sustained minimal residual disease (MRD) negativity rates, reinforcing the potential of CARVYKTI to transform outcomes in refractory multiple ...